Skip to content
Conditions & Health

Obesity

A chronic disease defined by BMI ≥ 30, characterized by excess adipose tissue. GLP-1 agonists have revolutionized obesity treatment, with semaglutide (Wegovy) and tirzepatide (Zepbound) achieving 15–25% weight loss.

Frequently Asked Questions

What is Obesity?
A chronic disease defined by BMI ≥ 30, characterized by excess adipose tissue. GLP-1 agonists have revolutionized obesity treatment, with semaglutide (Wegovy) and tirzepatide (Zepbound) achieving 15–25% weight loss.
Why is Obesity important in peptide research?
Understanding obesity is important because it represents a health condition where peptide interventions are being actively researched. Knowledge of the underlying pathology helps inform peptide selection and protocol design.

Related Terms

Metabolic syndrome

A cluster of conditions including central obesity, elevated blood sugar, high blood pressure, and abnormal cholesterol that together increase the risk of heart disease, stroke, and type 2 diabetes.

Lipolysis

The metabolic process of breaking down stored triglycerides into free fatty acids and glycerol for energy use. Stimulated by growth hormone, GH fragments (AOD-9604), and GLP-1 receptor agonists.

Lipogenesis

The metabolic process of synthesizing fatty acids and triglycerides for fat storage. Occurs primarily in the liver and adipose tissue. Inhibited by peptides like AOD-9604 and growth hormone fragments.

Related Peptide Profiles

Semaglutide

A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and weight management (Wegovy). Reduces appetite and slows gastric emptying.

Tirzepatide

A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and weight loss (Zepbound). Achieves 20–25% body weight reduction in clinical trials.

Retatrutide

An investigational triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed 24.2% weight loss at 48 weeks.

← Back to full glossary